{"id":"NCT00600886","sponsor":"Novartis Pharmaceuticals","briefTitle":"Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly","officialTitle":"A Multicenter, Randomized, Blinded Study to Assess Safety and Efficacy of Pasireotide LAR vs. Octreotide LAR in Patients With Active Acromegaly","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-02-11","primaryCompletion":"2016-03-11","completion":"2016-03-11","firstPosted":"2008-01-25","resultsPosted":"2015-01-30","lastUpdate":"2017-07-02"},"enrollment":358,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Acromegaly"],"interventions":[{"type":"DRUG","name":"Pasireotide","otherNames":["SOM230"]},{"type":"DRUG","name":"Octreotide","otherNames":[]}],"arms":[{"label":"Pasireotide LAR","type":"EXPERIMENTAL"},{"label":"Octreotide LAR","type":"ACTIVE_COMPARATOR"}],"summary":"The patients received either Pasireotide LAR or Octreotide LAR for one year of treatment.\n\nThe objective of this study was to compare the proportion of patients with a reduction of mean GH level to \\<2.5 µg/L and the normalization of IGF-1 to within normal limits (age and sex related) between the two treatment groups (pasireotide LAR and octreotide LAR) at 12 months.\n\nFollowing one year of treatment patients could proceed into the study extension.\n\nPatients who did not respond to the treatment they were randomized to (based on month 12 assessment results) were switched to the other treatment arm at month 13.","primaryOutcome":{"measure":"Percentage of Participants With a Reduction of Mean GH Level to <2.5 μg/L and the Normalization of IGF-1","timeFrame":"12 months","effectByArm":[{"arm":"Pasireotide LAR (Core)","deltaMin":31.3,"sd":null},{"arm":"Octreotide LAR (Core)","deltaMin":19.2,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.007"},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":4},"locations":{"siteCount":95,"countries":["United States","Argentina","Belgium","Brazil","Canada","China","Colombia","Czechia","Denmark","France","Germany","Greece","Hungary","Israel","Italy","Mexico","Netherlands","Norway","Poland","Russia","South Korea","Spain","Sweden","Switzerland","Taiwan","Turkey (Türkiye)","United Kingdom"]},"refs":{"pmids":["27039081","26437217","25103549"],"seeAlso":["http://www.novartisclinicaltrials.com/webapp/etrials/searchTrial.do?trialID=660"]},"adverseEventsSummary":{"seriousAny":{"events":35,"n":178},"commonTop":["Diarrhoea","Cholelithiasis","Hyperglycaemia","Headache","Nasopharyngitis"]}}